Research progress on management strategies for dyslipidemia in the elderly

doi:10.3877/cma.j.issn.2095-8757.2026.01.001

Abstract

Abstract:

Atherosclerotic Cardiovascular Disease (ASCVD) is a major cause of death and disability among the elderly, and hyperlipidemia is one of the key risk factors. The elderly population constitutes the main group affected by dyslipidemia. Clinical studies have confirmed that lipid management significantly reduces the morbidity and mortality of ASCVD in the elderly. Therefore, how to strengthen lipid management in the elderly under the premise of multiple comorbidities and polypharmacy has become a hot topic in the field of geriatric medicine. This article systematically reviews the lipid profiles of the elderly, recent research advances in lipid-lowering drugs, and clinical management strategies, aiming to provide guidance for the standardized management of dyslipidemia in older adults.

Key words: Aged, Lipid, Management, Atherosclerotic cardiovascular disease

Liming Hou, Xiaoming Wang. Research progress on management strategies for dyslipidemia in the elderly[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2026, 13(01): 1-6.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2026.01.001

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2026/V13/I01/1

References 36

[1]	国家卫生健康委疾病预防控制局.中国居民营养与慢性病状况报告（2020年）[M].北京：人民卫生出版社，2022：73-76.
[2]	海峡两岸医药卫生交流协会老年医学专业委员会.≥75岁老年患者血脂异常管理的专家共识[J].中国心血管杂志，2020，25（3）：201-209.
[3]	Song R, Hu M, Qin X, et al. The roles of lipid metabolism in the pathogenesis of chronic diseases in the elderly[J]. Nutrients, 2023, 15(15):3433-3450.
[4]	Ballantyne CM, Varughese MG, Abushamat LA. Lipid-lowering therapy in the elderly: Are current guidelines a sign of ageism in medical care?[J]. J Am Coll Cardiol, 2023, 81(14):1350-1352.
[5]	Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis: Evidence and practical applications[J]. Nat Rev Cardiol, 2024, 21(10):701-716.
[6]	Chen X, Zhao X, Fei H, et al. Combined association of triglyceride-glucose index and the atherogenic index of plasma with the incidence of cardiovascular diseases among middle-aged and older population[J]. Cardiovasc Diabetol, 2025, 25(1):19.
[7]	Qian T, Sheng X, Shen P, et al. Mets-IR as a predictor of cardiovascular events in the middle-aged and elderly population and mediator role of blood lipids[J]. Front Endocrinol (Lausanne), 2023, 14:1224967.
[8]	Hang B, Wang Y. Interplay between gut microbiota and intestinal lipid metabolism:mechanisms and implications[J]. J Zhejiang Univ Sci B, 2025, 26(10):961-971.
[9]	Xiao Y, Yang M, Cai M, et al. EGCG and taurine synergistically ameliorate lipid metabolism disorder by modulating gut microbiota and PPARalpha/FAS signaling pathway[J]. Nutrients, 2025, 17(16):2595.
[10]	Xu D, Feng M, Chu Y, et al. The prebiotic effects of oats on blood lipids, gut microbiota, and short-chain fatty acids in mildly hypercholesterolemic subjects compared with rice: A randomized, controlled trial[J]. Front Immunol, 2021, 9(12):787-797.
[11]	You M, Zhou L, Wu F, et al. Probiotics for the treatment of hyperlipidemia: Focus on gut-liver axis and lipid metabolism[J]. Pharmacol Res, 2025, 214:107694.
[12]	中国血脂管理指南修订联合专家委员会.中国血脂管理指南（2023年）[J].中华心血管病杂志，2023 ，51（3）：221-255.
[13]	Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias[J]. Eur Heart J, 2025, 46(42):4359-4378.
[14]	刘梅林，张雨濛，付志方，等.老年人血脂异常管理中国专家共识[J].中华内科杂志，2022，61（10）：1095-1118.
[15]	Lee SH, Lee YJ, Heo JH, et al. Combination moderate-intensity statin and ezetimibe therapy for elderly patients with atherosclerosis[J]. J Am Coll Cardiol, 2023, 81(14):1339-1349.
[16]	Huh J, Kim H. Naturally occurring PCSK9 inhibitors: An updated review[J]. Molecules, 2025, 30(17):3582-3600.
[17]	Khan SU, Yedlapati SH, Lone AN, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: A systematic review and network meta-analysis[J]. BMJ, 2022, 377:e069116.
[18]	黄进宇.2024年欧洲心脏病学会血脂热点速递[J].心电与循环，2025，44（2）：113-117.
[19]	Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an ex tended-term follow-up: The ORION-8 trial[J]. Cardiovasc Res, 2024, 120(12):1400-1410.
[20]	Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: The ORION-11 trial[J]. Eur Heart J, 2022, 43(48):5047-5057.
[21]	Leiter LA, Raal FJ, Schwartz GG, et al. Inclisiran in individuals with diabetes or obesity: Post hoc pooled an alyses of the ORION-9, ORION-10 and ORION-11 phase 3 randomized trials[J]. Diabetes Obes Metab, 2024, 26(8):3223-3237.
[22]	Huo Y, Lesogor A, Lee CW, et al. Efficacy and safety of inclisiran in Asian patients: Results from ORIO N-18[J]. JACC Asia, 2023, 4(2):123-134.
[23]	Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: One-year follow-up of the ORION-1 randomized clinical trial[J]. JAMA Cardiol, 2019, 4(11):1067-1075.
[24]	黄燕莹，王京丽，曾平.英克司兰治疗高龄颈动脉斑块患者1例[J].现代医学与健康研究电子杂志，2024，8（16）：23-27.
[25]	Reyes-Soffer G, Ginsberg HN, Berglund L, et al. American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein (a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association[J]. Arterioscler Thromb Vasc Biol, 2022, 42(1): e48-e60.
[26]	Madsen CM, Kamstrup PR, Langsted A, et al. Lipoprotein (a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: A population-based study[J]. Arterioscler Thromb Vasc Biol, 2020, 40(1):255-266.
[27]	Cho L, Nicholls SJ, Nordestgaard BG, et al. Design and rationale of Lp(a)HORIZON trial: Assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)[J]. Am Heart J, 2025, 287:1-9.
[28]	O'Donoghue ML, Rosenson RS, López JAG, et al. The off-treatment effects of olpasiran on lipoprotein(a) lowering: OCEAN(a)-DOSE extension period results[J]. J Am Coll Cardiol, 2024, 84(9):790-797.
[29]	Xie X, Shi X, Zhang Y, et al. Angiopoietin-like 3 antibody therapy in patients with suboptimally controlled hyperlipidemia: A phase 2 study[J]. J Am Coll Cardiol, 2025, 85(19):1821-1835.
[30]	Ballantyne CM, Banka P, Mendez G, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616[J]. J Am Coll Cardiol, 2023, 81(16):1553-1564.
[31]	Hooper AJ, Tang XL, Burnett JR. VERVE-101, a CRISPR base-editing therapy designed to permanently inact ivate hepatic PCSK9 and reduce LDL-cholesterol[J]. Expert Opin Investig Drugs, 2024, 33(8):753-756.
[32]	Gouni-Berthold I, Schwarz J, Berthold HK. Updates in drug treatment of severe hypertriglyceridemia[J]. Curr Atheroscler Rep, 2023, 25(10):701-709.
[33]	Bittner V, Linnebur SA, Dixon DL, et al. Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An expert clinical consensus from the national lipid association and the American geriatrics society[J]. J Am Geriatr Soc, 2025, 73(6):1674-1696.
[34]	李建军.《2025ESC/EAS关于2019年血脂管理指南重点更新》解读[J].临床心血管病杂志，2025，41（10）：755-756.
[35]	Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the national lipid association[J]. J Clin Lipidol, 2024, 18(5):e647-e663.
[36]	Tsimikas S, Bittner V. Particle number and characteristics of lipoprotein(a), LDL, and apoB: Perspectives on contributions to ASCVD[J]. J Am Coll Cardiol, 2024, 83(3):396-400.

Please choose a citation manager

Content to export